Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apex BiotechnologyTPE:1733 82 EV-to-FCF is 9.82 as of Sep. 03, 2026, which is 25% below its 10-year median of 13.10. GuruFocus rates TPE:1733 with a GF Score™ of 82/100 and a GF Value™ of NT$30.00 (Fairly Valued). The stock has 3 warning signs investors should review. Among 314 Biotechnology companies, Apex Biotechnology ranks better than 62.74% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Apex Biotechnology's Enterprise Value is NT$2,554 Mil.
Apex Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$260 Mil. Therefore, Apex Biotechnology's EV-to-FCF for today is 9.82.
The historical rank and industry rank for Apex Biotechnology's EV-to-FCF or its related term are showing as below:
TPE:1733'
s EV-to-FCF Range Over the Past 10 Years
Min: -549.22 Med: 13.1 Max: 136.37
Current: 9.76
During the past 13 years, the highest EV-to-FCF of Apex Biotechnology was 136.37. The lowest was -549.22. And the median was 13.10.
TPE:1733's EV-to-FCF is ranked better than 62.74% of 314
companies
in the Biotechnology industry
Industry Median: 16.735
vs TPE:1733: 9.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Apex Biotechnology's PE Ratio (TTM) for today is calculated as:
Apex Biotechnology's share price for today is NT$32.25.
Apex Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Apex Biotechnology EV-to-FCF Related Terms
Apex Biotechnology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, MRNA: EV-to-FCF Comparison
For the Biotechnology subindustry, Apex Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's EV-to-FCF falls into.
Apex Biotechnology's current Enterprise Value is NT$2,554 Mil.
Apex Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$260 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a EV-to-FCF of 9.82 as of Sep. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Apex Biotechnology and its competitors. This is 25% below median its historical median of 13.10. According to the industry distribution chart, Apex Biotechnology ranks #117 out of 314 companies in the Biotechnology industry, placing it in the top 37.3%.
Is Apex Biotechnology's EV-to-FCF too high?
Apex Biotechnology's current EV-to-FCF of 9.82 is 25% below median its 10-year median of 13.10. The Biotechnology industry median EV-to-FCF is 16.74. Apex Biotechnology's value of 9.82 is 41.3% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #117 out of 314 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #117 out of 314 companies for EV-to-FCF. This puts Apex Biotechnology in the upper half of its industry. The industry median EV-to-FCF is 16.74. Apex Biotechnology's value of 9.82 is 41.3% below this benchmark. While the company's 10-year median is 13.10 vs. the industry median of 16.74, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.74, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current EV-to-FCF of 9.82 is 41.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current EV-to-FCF is 9.82, which is 25% below median its own 10-year median of 13.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.00, compared to a current price of NT$32.25 — trading 7.5% above its estimated fair value. The current EV-to-FCF is 9.82, which is 25% below median its 10-year median of 13.10 and 41.3% below the Biotechnology industry median of 16.74. Apex Biotechnology's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current EV-to-FCF is 9.82 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$32.25 is trading 7.5% above its estimated GF Value™ of NT$30.00.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
EV-to-FCF: 9.82 (25% below median its 10-year median of 13.10)
GF Value™: NT$30.00 vs. price of NT$32.25 (7.5% above fair value)
Industry Position: 41.3% below the Biotechnology median (#117 of 314)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
82GF Score
Get the complete analysis for TPE:1733
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
